Anika Therapeutics (NASDAQ:ANIK – Get Free Report) had its price objective reduced by research analysts at Barrington Research from $25.00 to $20.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Barrington Research’s price objective points to a potential upside of 25.71% from the company’s current price.
Anika Therapeutics Stock Up 4.6 %
NASDAQ:ANIK opened at $15.91 on Thursday. Anika Therapeutics has a twelve month low of $14.95 and a twelve month high of $29.11. The business has a 50 day moving average price of $16.90 and a two-hundred day moving average price of $19.55. The company has a market cap of $233.02 million, a P/E ratio of -2.39 and a beta of 0.95.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last released its quarterly earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.13). Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. The firm had revenue of $30.60 million for the quarter, compared to analyst estimates of $29.00 million. As a group, analysts anticipate that Anika Therapeutics will post -0.84 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Anika Therapeutics
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Read More
- Five stocks we like better than Anika Therapeutics
- ESG Stocks, What Investors Should Know
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Most active stocks: Dollar volume vs share volume
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Election Stocks: How Elections Affect the Stock Market
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.